Sakar Healthcare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sakar Healthcare reported a strong Q1 FY26 with revenue from operations rising to Rs. 5,273.62 lakh, up about 28% from Rs. 4,114.77 lakh in Q1 FY25. Profit after tax nearly doubled to Rs. 467.13 lakh (vs Rs. 241.20 lakh), translating to an EPS of Rs. 2.11 (vs Rs. 1.10). The board also fixed the 21st AGM for September 23, 2025, approved appointment of three new Independent Directors, three senior management hires (COO, SVP Finance, SVP International Business), and appointed Secretarial and Cost Auditors. The company issued 3 lakh equity shares on conversion of warrants, raising Rs. 8.64 crore, with funds being used for loan repayment and oncology unit capex as planned, with no deviations reported. Auditor J.S. Shah & Co. issued a clean (unqualified) limited review report on both standalone and consolidated results.
Sharp revenue growth (~28%) and nearly doubled profits signal strong operational momentum for shareholders. The clean audit report, zero loan defaults, and on-track use of warrant conversion funds are positive; the board expansion and senior management additions suggest focus on scaling operations, particularly international business and the oncology segment.